Replies to post #360659 on Amarin Corp Plc (AMRN)

[momoney24]

KM made a reference to this during the investor presentation with Jeffries the other day

[Birdbrain Ideas]

KM said so the other day. Check out Post 360585.

However, I can repeat the relevant part.

Fascinating that he essentially was threatening to sue two pharmacy chains (he didn't say 'pharmacy chains' but I can't imagine what else it could be) if they continue to fail to update the medical references that pharmacists use to fulfill prescriptions. He says they are not showing the accurate indication of Vascepa and the generic. They either show that Vascepa and the generic are both indicated for cardiovascular risk reduction. Or, they don't show any cardiovascular risk reduction.

"For many of us, that was a big surprise," he said. He said one of three of what I suspect are pharmacy chains "realized that there was a big mistake there, corrected it, last month, but two, still have not corrected it. And we are at the time where we are basically considering all of our options, including the legal one. Because if they don't update their references with the accurate indication, the pharmacy fulfillment system will continue to read that the generic is equal to the brand, which is not the case. It's only equal to the brand if the patient has more than 500 ... triglycerides."

He also said that those medical references put out by pharmacy units are read by doctors as well. So the misinformation is further misinforming doctors to think that generics are on a level playing field with Amarin.